Clinical Trial Update: The Effects of Therapy With Teriparatide on Vascular Compliance and Osteoprotegerin/RANKL [NA]

View source ↗

Summary

A clinical trial evaluating the effects of teriparatide on vascular function and the OPG/RANKL pathway in osteoporosis has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoporosis

Drugs mentioned

• Forteo (Teriparatide) (Teriparatide)

Snippet

Sponsor: Leland Graves III, MD | Conditions: Osteoporosis | NA | Status: WITHDRAWN